CY1109956T1 - Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη - Google Patents

Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη

Info

Publication number
CY1109956T1
CY1109956T1 CY20091100181T CY091100181T CY1109956T1 CY 1109956 T1 CY1109956 T1 CY 1109956T1 CY 20091100181 T CY20091100181 T CY 20091100181T CY 091100181 T CY091100181 T CY 091100181T CY 1109956 T1 CY1109956 T1 CY 1109956T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
donepezil
solid pharmaceutical
hydrochlorine
composition included
Prior art date
Application number
CY20091100181T
Other languages
English (en)
Inventor
Miha Vrbinc
Berta Kotar-Jordan
Rok Zupet
Matej Smrkolj
Original Assignee
Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35464350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109956(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka, Tovarna Zdravil, D.D., Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D., Novo Mesto
Publication of CY1109956T1 publication Critical patent/CY1109956T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση αφορά μια στερεή φαρμακευτική σύνθεση περιλαμβάνουσα ένυδρο υδροχλωρική ντονεπεζίλη και μέθοδο για την παρασκευή αυτής. Συγκεκριμένα αφορά μια σύνθεση και μια μέθοδο, όπου η υδροχλωρική ντονεπεζίλη διατηρεί την πολυμορφική μορφή αυτής και συνεπώς είναι πολύ σταθερή έναντι μετατροπής σε άλλες πολυμορφικές μορφές.
CY20091100181T 2004-10-19 2009-02-18 Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη CY1109956T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004051055 2004-10-19
EP05795965A EP1811957B1 (en) 2004-10-19 2005-10-19 Solid pharmaceutical composition comprising donepezil hydrochloride

Publications (1)

Publication Number Publication Date
CY1109956T1 true CY1109956T1 (el) 2014-09-10

Family

ID=35464350

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100181T CY1109956T1 (el) 2004-10-19 2009-02-18 Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη

Country Status (19)

Country Link
US (3) US20090130205A9 (el)
EP (3) EP2039349A1 (el)
JP (1) JP2008517022A (el)
AT (1) ATE415148T1 (el)
CA (1) CA2584547C (el)
CY (1) CY1109956T1 (el)
DE (1) DE602005011326D1 (el)
DK (1) DK1811957T3 (el)
EA (1) EA012220B1 (el)
ES (1) ES2317313T3 (el)
HR (1) HRP20090104T3 (el)
NO (1) NO20072494L (el)
PL (1) PL1811957T3 (el)
PT (1) PT1811957E (el)
RS (1) RS51271B (el)
SI (1) SI1811957T1 (el)
UA (1) UA83152C2 (el)
WO (1) WO2006045512A1 (el)
ZA (1) ZA200704023B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515803D0 (en) * 2005-07-30 2005-09-07 Pliva Hrvatska D O O Intermediate compounds
DE102005060377A1 (de) 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
JP2009537538A (ja) * 2006-05-15 2009-10-29 アカドイア プハルマセウチカルス インコーポレーテッド ピマバンセリン医薬製剤
GB0614586D0 (en) * 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
AU2008207864B2 (en) * 2007-01-24 2013-07-11 Cook Biotech Incorporated Biofilm-inhibiting medical products
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
DE102007037932A1 (de) * 2007-08-11 2009-02-12 Alfred E. Tiefenbacher Gmbh & Co.Kg Donepezilhydrochlorid in amorpher Form enthaltende Tablette
DE102009041839A1 (de) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Donepezil-haltige Tabletten
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
DE102010010998A1 (de) * 2010-03-10 2011-09-15 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung, umfassend Donepezil-Hydrochlorid der kristallinen polymorphen Form I
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
JP6093707B2 (ja) * 2010-11-30 2017-03-08 ウィスタ ラボラトリーズ リミテッド 化合物製剤
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
US20150216849A1 (en) 2014-02-04 2015-08-06 Forest Laboratories Holdings Ltd. Donepezil compositions and methods of treating alzheimers disease
CN114272219B (zh) * 2021-12-30 2023-11-10 江苏豪森药业集团有限公司 一种盐酸多奈哌齐片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
SK285312B6 (sk) 1996-06-07 2006-10-05 Eisai Co., Ltd. Polymorf (III) donepezil hydrochloridu, spôsob jeho výroby a terapeutický prostriedok s jeho obsahom
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
AU1153097A (en) * 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
AU755062B2 (en) * 1997-02-07 2002-12-05 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
CN1195862C (zh) * 1998-02-19 2005-04-06 札幌啤酒株式会社 分离和纯化的包括在蛇麻腺中特异性表达的基因的核酸
ATE254928T1 (de) * 1999-03-31 2003-12-15 Eisai Co Ltd Stabilisierte zusammensetzung mit nootropen wirkstoffen
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1260215E (pt) * 2000-03-01 2009-09-03 Eisai R&D Man Co Ltd Comprimido de desintegração rápida que contém poli(álcool vinílico)
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192180B (el) * 2001-09-28 2004-03-06 Ranbaxy Lab
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics

Also Published As

Publication number Publication date
EP2039349A1 (en) 2009-03-25
US20120283291A1 (en) 2012-11-08
PL1811957T3 (pl) 2009-05-29
WO2006045512A1 (en) 2006-05-04
DE602005011326D1 (de) 2009-01-08
EP1811957B1 (en) 2008-11-26
US20090130205A9 (en) 2009-05-21
ES2317313T3 (es) 2009-04-16
EP2283811A1 (en) 2011-02-16
PT1811957E (pt) 2009-01-27
UA83152C2 (ru) 2008-06-10
DK1811957T3 (da) 2009-03-30
EP1811957A1 (en) 2007-08-01
NO20072494L (no) 2007-07-02
SI1811957T1 (sl) 2009-04-30
CA2584547C (en) 2014-07-08
ATE415148T1 (de) 2008-12-15
US20080063705A1 (en) 2008-03-13
EA200700673A1 (ru) 2007-10-26
JP2008517022A (ja) 2008-05-22
CA2584547A1 (en) 2006-05-04
HRP20090104T3 (en) 2009-03-31
ZA200704023B (en) 2008-04-30
US20100317694A1 (en) 2010-12-16
RS51271B (sr) 2010-12-31
EA012220B1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
CY1109956T1 (el) Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη
FR22C1008I2 (fr) Composition immunogène
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
DK1711494T3 (da) Arylsubstituerede heterocykler, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
IS8136A (is) N-pýrrólidín-3-ýl-amíð afleiður sem serótónín og noradrenalín endurupptöku hindrar
DK3090748T3 (da) Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
DK2444806T3 (da) Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
NO20053569D0 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
IS7980A (is) Díarýlmetýlídenpíperidínafleiður, framleiðsla þeirra og notkun
DK1587478T3 (da) Farmaceutisk sammensætning
BRPI0614413A2 (pt) composto, e, composição farmacêutica
DK1611115T3 (da) Benzothiazolderivatforbindelser, sammensætninger og anvendelser deraf
DK1600207T3 (da) Emulgator, fremgangsmåde til fremstilling deraf og emulgeret sammensætning der anvender emulgatoren
DK1778265T3 (da) Guanylhydrazoneforbindelser, sammensætninger, fremgangsmåder og anvendelse
NO20053598L (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
DK1816121T3 (da) 9-chlor-15-deoxyprostaglandinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som medikamenter
DK1906921T3 (da) Klar farmaceutisk, vandig mikroemulsion omfattende propofol og fremgangsmåde til fremstilling
DK1931304T3 (da) Hidtil ukendt anvendelse til en sammensætning, der omfatter chlorprocain-HCl, en hidtil ukendt sammensætning, der omfatter chlorprocain-HCl og en fremgangsmåde til fremstilling deraf
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
ITRM20070222A1 (it) Derivati 1,3,4 tiadiazolici metodi di preparazione e uso di essi